Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
73,657,574
-
Total 13F shares
-
5,303,151
-
Share change
-
-916,357
-
Total reported value
-
$3,177,608
-
Price per share
-
$0.60
-
Number of holders
-
48
-
Value change
-
-$311,761
-
Number of buys
-
16
-
Number of sells
-
20
Institutional Holders of RELMADA THERAPEUTICS, INC. - Common Stock (RLMD) as of Q2 2025
As of 30 Jun 2025,
RELMADA THERAPEUTICS, INC. - Common Stock (RLMD) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,303,151 shares.
The largest 10 holders included
Driehaus Capital Management LLC, ACADIAN ASSET MANAGEMENT LLC, BlackRock, Inc., AdvisorShares Investments LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, DEUTSCHE BANK AG\, Corient Private Wealth LLC, UBS Group AG, and PARSONS CAPITAL MANAGEMENT INC/RI.
This page lists
48
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.